N-acetylglucosaminyltransferase V gene

Overview

Information

Number
5602003
Application
08/016863
Filing date
02/10/1993
Issue date
02/11/1997
Inventor(s)
J. Michael Pierce, Mohamed G. Shoreibah, Beverly S. Adler, Nevis L. Fregien
US Classification
435/193; 435/252.3; 435/252.33; 435/320.1; 435/325; 435/365; 435/69.1; 435/70.1; 536/23.2; 536/23.5
View at USPTO

Citations

Abstract

Abstract

The present invention provides a substantially purified UDP-N-acetylglucosamine:.alpha.-6-D-mannoside .beta.-1,6-N-acetylglucosaminyltransferase (GlcNAc T-V; EC 2.4.1.155) and antibodies which specifically bind GlcNAc T-V. The present invention also provides polynucleotide sequences and oligonucleotide probes capable of specifically hybridizing to nucleic acid sequences which encode GlcNAc T-V, and cDNA and genomic clones encoding GlcNAc T-V, as well as nucleotide sequences encoding GlcNAc T-V, as specifically exemplified by a GlcNAc T-V coding sequence from rat.

Assignees with Similar Patents

Referenced by

GlycoFi (21)
UNIVERSITY OF GEORGIA, THE (2)
Schering (1)
Merck & co. (1)
GLYCODesign (1)

Tech Analysis

Class Subclass Type Reference Factor Citation Factor Strength Grant time Early grant (%)
435 193 Emerging Novel Seminal High Average 71.9
435 252.3 Emerging Average Seminal Medium High Average 72.4
435 252.33 Emerging Average Seminal Medium High Average 74.0
435 320.1 Emerging Average Seminal Medium High Average 68.5
435 325 Emerging Novel Seminal High Average 63.8
435 365 Declining Average Seminal Medium High Average 69.8
435 69.1 Emerging Average Seminal Medium High Average 67.9
435 70.1 Emerging Novel Seminal High Average 70.7
536 23.2 Emerging Average Seminal Medium High Average 73.0
536 23.5 Emerging Average Seminal Medium High Average 66.6